Equities Analysts Issue Forecasts for Genmab A/S Q3 Earnings

Genmab A/S (NASDAQ:GMAB) – Stock analysts at HC Wainwright lowered their Q3 2024 earnings estimates for shares of Genmab A/S in a report issued on Wednesday, October 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.34 per share for the quarter, down from their previous forecast of $0.35. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.27 per share. HC Wainwright also issued estimates for Genmab A/S’s FY2024 earnings at $1.36 EPS.

Several other research firms also recently commented on GMAB. Morgan Stanley restated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. Redburn Atlantic assumed coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a “buy” rating for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. BTIG Research boosted their target price on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Finally, Royal Bank of Canada upgraded Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $22.78 on Monday. The business has a 50-day simple moving average of $25.66 and a 200 day simple moving average of $27.01. Genmab A/S has a one year low of $22.52 and a one year high of $32.89. The firm has a market capitalization of $15.06 billion, a price-to-earnings ratio of 18.98, a PEG ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). The company had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in shares of Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after purchasing an additional 544 shares during the last quarter. GAMMA Investing LLC increased its holdings in Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after buying an additional 749 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in Genmab A/S in the first quarter worth about $43,000. Blue Trust Inc. grew its position in shares of Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares during the period. Finally, Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.